Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor
A phase 3 trial of Cabergoline in Pituitary tumours, run by Seth Gordhandas Sunderdas Medical College, completed.
Overview
Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor is a phase 3 interventional study registered as NCT00889525 by Seth Gordhandas Sunderdas Medical College, started 2007-11. Interventions recorded: Cabergoline. Conditions recorded: Cushing's Disease, Corticotroph Adenoma.
Linked to the drug Cabergoline because the registry names it among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialCabergoline in Nonfunctioning Pituitary Adenomas
Shares Cabergoline, Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialSafety and Potency of a High Cabergoline Dosage in Microprolactinomas
Shares Cabergoline, Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialMulticenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialSafety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialEfficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialStrict IGF-1 Control in Acromegaly
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialA Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialSafety and Efficacy of LCI699 in Cushing's Disease Patients
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.